Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AZD5069 add-on therapy in uncontrolled persistent asthma
2012-001869-33Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azd5069 in asthma (4 arms), sponsored by AstraZeneca. Primary endpoint: Rate of severe asthma exacerbations during 6 months. Started Aug 2012; status: terminated.
02
Drugs
azd5069
03
Conditions
asthma
Beyond the preview
Go deeper on 2012-001869-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001869-33.